(3.238.174.50) 您好!臺灣時間:2021/04/18 17:50
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:黃雅蓮
研究生(外文):Ya-Lien Huang
論文名稱:針對化療或造血幹細胞移植所引起嗜中性白血球低下病患預防侵入性黴菌感染之統合分析
論文名稱(外文):Prophylaxis of Invasive Fungal Infection in Patients with Neutropenia Related to Chemotherapy or Hematologic Stem Cell Transplantation
指導教授:林淑娟林淑娟引用關係
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:藥學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2012
畢業學年度:100
語文別:英文
論文頁數:135
中文關鍵詞:侵入性黴菌感染;預防性抗黴菌藥物;統合分析
外文關鍵詞:Invasive fungal infectionprophylaxis antifungal agentsmeta-analysis
相關次數:
  • 被引用被引用:0
  • 點閱點閱:232
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Acknowledgments IV
Contents V
List of Tables VII
List of Figures VIII
List of Appendix X
Abstract in Chinese XI
Abstract in English XIII
1 Introduction 1
1.1 Definition of invasive fungal infection 4
1.2 Strategies for prevention and treatment of
invasive fungal infection 5
2 Systemic Review 7
3 Methods 13
3.1 Criteria for considering studies 13
3.2 Search methods for identification of studies 14
4 Results 18
4.1 Characteristics of included studies 20
4.2 Excluded studies 82
4.3 Systemic antifungals versus placebo, no
treatment, or nonsystemic antifungals 83
4.4 Systemic antifungals versus other systemic
antifungals 93
5 Discussion 109
6 Conclusion 112
References 114


1.Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. The American journal of medcine 2012;125:S3-13.
2.Blijlevens NMA, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. British journal of haematology 2002;117:259-64.
3.Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clinical infectious diseases 2001;33:1959-67.
4.Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997;19:801-8.
5.Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical infectious diseases 2002;34:909-17.
6.Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
7.Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15-9.
8.Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. The Journal of infectious diseases 1997;175:1459-66.
9.Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England journal of medicine 2007;356:335-47.
10.Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. Cancer 2000;89:1611-25.
11.Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. European journal of clinical microbiology & infectious diseases 2006;25:549-61.
12.Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies. Clinical infectious diseases 1999;28:250-5.
13.Walsh TJ. Echinocandins--an advance in the primary treatment of invasive candidiasis. The New England journal of medicine 2002;347:2070-2.
14.Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 2002;48:78-81.
15.Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies. British journal of haematology 2005;131:22-8.
16.Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies. Journal of clinical oncology 2003;21:4615-26.
17.Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients. Cancer 2002;94:3230-46.
18.Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation. Journal of clinical oncology 2007;25:5471-89.
19.Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants. Clinical infectious diseases 2002;34:7-14.
20.De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical infectious diseases 2008;46:1813-21.
21.Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clinical infectious diseases 2007;44:402-9.
22.Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. The Journal of the American Medical Association 1992;268:240-8.
23.Oxman AD, Guyatt GH. The science of reviewing research. Annals of the New York Academy of Sciences 1993;703:125-33; discussion 33-4.
24.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5. 1. 0; 2011.
25.Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-analysis in context. Second edition; 2001.
26.Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-8.
27.Annaloro C, Oriana A, Tagliaferri E, et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995;80:512-7.
28.Benhamou E, Hartmann O, Nogues C, et al. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Bone marrow transplantation 1991;7:127-31.
29.Bodey GP, Anaissie EJ, Elting LS, Estey E, O''Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106.
30.Boogaerts M, Maertens J, van Hoof A, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. The Journal of antimicrobial chemotherapy 2001;48:97-103.
31.Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematology and blood transfusion 1990;33:546-50.
32.Cattaneo C, Monte S, Algarotti A, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). The Journal of antimicrobial chemotherapy 2011;66:2140-5.
33.Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994;40:136-43.
34.Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England journal of medicine 2007;356:348-59.
35.Donnelly JP, Starke ID, Galton DA, et al. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. The Journal of hospital infection 1984;5:83-91.
36.Egger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. Supportive care in cancer 1995;3:139-46.
37.Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. European journal of clinical microbiology & infectious diseases 1994;13:3-11.
38.Estey E, Maksymiuk A, Smith T, et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Archives of internal medicine 1984;144:1562-8.
39.Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. The Journal of antimicrobial chemotherapy 2006;57:317-25.
40.Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. The New England journal of medicine 1992;326:845-51.
41.Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-9.
42.Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia. Antimicrobial agents and chemotherapy 2000;44:1887-93.
43.Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. International journal of hematology 2008;88:588-95.
44.Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. Journal of clinical pathology 1999;52:376-80.
45.Ito Y, Ohyashiki K, Yoshida I, et al. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes. International journal of hematology 2007;85:121-7.
46.Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. Journal of infection and chemotherapy 2003;9:40-5.
47.Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients. Bone marrow transplantation 1999;23:163-8.
48.Kern W, Behre G, Rudolf T, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Cancer 1998;83:291-301.
49.Koh LP, Kurup A, Goh YT, et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. American journal of hematology 2002;71:260-7.
50.Lass-Florl C, Gunsilius E, Gastl G, et al. Fungal colonization in neutropenic patients. Annals of hematology 2003;82:565-9.
51.Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Journal of antimicrobial chemotherapy 2000;46:1001-8.
52.MacMillan ML, Goodman JL, DeFor TE, et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients. The American journal of medicine 2002;112:369-79.
53.Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction. Journal of pediatric hematology/oncology 2011;33:e333-41.
54.Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
55.Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:450-6.
56.Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrobial agents and chemotherapy 2006;50:143-7.
57.Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Supportive care in cancer 2011;19:19-26.
58.Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Annals of internal medicine 1994;120:913-8.
59.Meunier-Carpentier F, Cruciani M, Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. European journal of cancer & clinical oncology 1983;19:43-8.
60.Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. British journal of haematology 1999;105:901-11.
61.Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. European journal of clinical microbiology & infectious diseases 1994;13:330-7.
62.Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clinical infectious diseases 2000;30:300-5.
63.Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone marrow transplantation 2006;38:127-34.
64.Palmblad J, Lonnqvist B, Carlsson B, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults. Journal of internal medicine 1992;231:363-70.
65.Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia. Annals of oncology 2006;17:1306-12.
66.Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. The Journal of infectious diseases 1992;165:891-7.
67.Philpott-Howard JN, Wade JJ, Mufti GJ, et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. The Journal of antimicrobial chemotherapy 1993;31:973-84.
68.Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. The American journal of medicine 1994;97:509-14.
69.Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients. Clinical infectious diseases 1999;28:331-40.
70.Rozenberg-Arska M, Dekker AW, Branger J, et al. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. The Journal of antimicrobial chemotherapy 1991;27:369-76.
71.Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. The Journal of infectious diseases 1995;172:1035-41.
72.Shepp DH, Klosterman A, Siegel MS, et al. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. The Journal of infectious diseases 1985;152:1257-63.
73.Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation. The Journal of infectious diseases 1995;171:1545-52.
74.Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone marrow transplantation 1993;12:577-82.
75.Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical infectious diseases 2004;39:1407-16.
76.Van Delden C, Lew DP, Chapuis B, et al. Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary? Clinical microbiology and infection 1995;1:24-30.
77.Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). The Journal of infection 2007;55:445-9.
78.Vogler WR, Malcom LG, Winton EF. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer investigation 1987;5:267-73.
79.Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. Leukemia & lymphoma 1993;11:353-8.
80.Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-8.
81.Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Annals of internal medicine 1993;118:495-503.
82.Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med 2003;138:705-13.
83.Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation. Bone marrow transplantation 2000;25:853-9.
84.Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgraduate medical journal 1995;71:284-6.
85.Young GA, Bosly A, Gibbs DL, Durrant S. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia. European journal of cancer 1999;35:1208-13.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔